News Archives - Inify Laboratories

Inify Laboratories – Extended subscription period

Investor News, News 2022-05-30

STOCKHOLM – May 30th, 2022 Inify Laboratories AB has decided to extend the Subscription Period in the ongoing Subsequent Offering to 3 June 2022 at 16:30 hours (CEST). As a consequence of this extension, the payment date will be on or about 8 June 2022 and delivery of shares will take place on or about […]

Inify Laboratories – extra bolagsstämma 2022-05-09

Investor News, News 2022-05-09

STOCKHOLM – 9 maj 2022 Inify Laboratories har hållit en extra bolagsstämma den 9 maj 2022. Bifogat finns en sammanfattning av de beslut som fattades vid den extra bolagsstämman. Vänligen kontakta: för frågor angående den extra stämman. Nedladdningar Sammanfattning Extra bolagsstämma 2022-05-09 (pdf)

Inify Laboratories – kallelse till extra bolagsstämma

Investor News, News, Uncategorized 2022-04-11

STOCKHOLM – 11 april 2022 Inify Laboratories bjuder härmed in sina aktieägare till en extra bolagsstämma den 9 maj 2022. Bifogat finns kallelse inklusive dagordning och information om hur man registrerar sig och röstar. Vänligen kontakta: för frågor angående den extra stämman. Nedladdningar Kallelse extra bolagsstämma (pdf) Anmälningsblankett bolagsstämma (pdf) Styrelsens redogörelse enligt 13 […]

INIFY Laboratories AB becomes an independent company

Home, Investor News, News 2021-12-10

STOCKHOLM – December 10, 2021 – ContextVision, a medical technology software company specializing in image processing, today announces that at the EGM of ContextVision on Dec 10th, it was resolved that the subsidiary INIFY Laboratories will become an independent company through a distribution of its shares to existing shareholders of ContextVision. The company will build […]

ContextVision to focus pathology efforts on the establishment of a fully AI-supported lab service

Home, Investor News, News 2021-11-15

ContextVision today announces that the Board of Directors of ContextVision has decided to make a strategic shift and focus its pathology business unit entirely on the establishment of an AI based pathology lab service.

ContextVision – Aiming to build the company’s first modern pathology lab

Financial reports, Home, Investor News, News 2021-10-21

ContextVision has decided to build its first fully digital pathology laboratory – thus confirming its strong dedication to advancing digitalization within pathology, for the best of both patients and the medical profession.

INIFY Prostate® shown to accurately outline suspicious prostate cancer in study with two prominent medical centers

Home, News 2021-10-18

ContextVision today announced that results from a US clinical evaluation were presented at the Pathology Visions Congress in Las Vegas, USA.

In the Pan-European multicenter clinical study FirstPath, INIFY Prostate produced highly accurate, robust and homogenous results at all sites

Home, News 2021-08-31

STOCKHOLM – August 31, 2021 – ContextVision, a medical technology software company specializing in image processing, image analysis and decision support tools for digital pathology, today announced that results from FirstPath – a European multicenter clinical study evaluating performance of INIFY® Prostate in routine clinical practice – were presented at the European Congress of Pathology by […]